A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Intepirdine (Primary)
- Indications Alzheimer's disease; Dementia; Lewy body disease; Parkinson's disease
- Focus Therapeutic Use
- Sponsors Axovant Sciences
- 07 Aug 2017 According to an Axovant Sciences media release, top-line results from the study are expected in fourth quarter 2017.
- 08 Jun 2017 Results are expected in 2017.
- 08 Jun 2017 Trial design presented at the 21st International Congress of Parkinson's Disease and Movement Disorders